Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

被引：10

作者：

Liu, Yi-Fu ^{[1
]}

Fu, Sheng-Qiang ^{[1
]}

Yan, Yu-Chang ^{[1
]}

Gong, Bin-Bin ^{[1
]}

Xie, Wen-Jie ^{[1
]}

Yang, Xiao-Rong ^{[1
]}

Sun, Ting ^{[1
]}

Ma, Ming ^{[1
]}

机构：

[1] Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330000, Jiangxi, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷

关键词：

gonadotropin-releasing hormone; prostate cancer; degarelix; relugolix; ANDROGEN-DEPRIVATION THERAPY; ANTIANDROGEN FLARE PROTECTION; URINARY-TRACT SYMPTOMS; III EXTENSION TRIAL; OF-LIFE IMPROVEMENT; OPEN-LABEL; GNRH ANTAGONIST; PHASE-II; JAPANESE PATIENTS; 1-ARM CROSSOVER;

D O I：

10.2147/DDDT.S291369

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice. Currently, the GnRH receptor antagonists used for endocrine therapy for prostate cancer primarily include degarelix and relugolix (TAK-385). The former is administered by subcutaneous injection, while the latter is an oral drug. Compared to GnRH agonists, GnRH antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges. This review focuses on the mechanism of action of GnRH antagonists and agonists, the developmental history of GnRH antagonists, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer.

引用

页码：639 / 649

页数：11

共 50 条

[31] Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists [J].

Tan, Orkun ;

Bukulmez, Orhan .

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2011, 23 (04) :238-244

[32] Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies [J].

Limonta, Patrizia ;

Manea, Marilena .

CANCER TREATMENT REVIEWS, 2013, 39 (06) :647-663

[33] Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment [J].

Elshimy, Ghada ;

Raj, Rishi ;

Jacob, Aasems ;

Correa, Ricardo .

BMJ CASE REPORTS, 2022, 15 (03)

[34] Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer [J].

Massoud, W ;

Paparel, P ;

Lopez, JG ;

Perrin, P ;

Daumont, M ;

Ruffion, A .

INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (01) :87-88

[35] Relationship Between Gonadotropin-Releasing Hormone/Gonadotropin-Releasing Hormone Receptor Signaling and Progesterone Receptors in Human Trophoblasts [J].

Lee, Bang Hyun ;

Kim, Jae Hoon ;

Park, Tae Chul ;

Lee, Hee Joong .

JOURNAL OF REPRODUCTIVE MEDICINE, 2016, 61 (5-6) :275-281

[36] Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases [J].

George, Gincy ;

Garmo, Hans ;

Scailteux, Lucie-Marie ;

Balusson, Frederic ;

De Coster, Greet ;

De Schutter, Harlinde ;

Kuiper, Josephina G. ;

Oger, Emmanuel ;

Verbeeck, Julie ;

Van Hemelrijck, Mieke .

INTERNATIONAL JOURNAL OF CANCER, 2021, 148 (09) :2203-2211

[37] Gonadotropin-Releasing Hormone Antagonists for Assisted Reproductive TechniquesAre There Clinical Differences Between Agents? [J].

Georg Griesinger ;

Ricardo E. Felberbaum ;

Askan Schultze-Mosgau ;

Klaus Diedrich .

Drugs, 2004, 64 :563-575

[38] Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues [J].

Kakar, SS ;

Jennes, L .

CANCER LETTERS, 1995, 98 (01) :57-62

[39] Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions [J].

Fontana, Fabrizio ;

Marzagalli, Monica ;

Montagnani Marelli, Marina ;

Raimondi, Michela ;

Moretti, Roberta M. ;

Limonta, Patrizia .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (24) :1-23

[40] A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients [J].

Yoshiyuki Miyazawa ;

Yoshitaka Sekine ;

Takahiro Syuto ;

Masashi Nomura ;

Hidekazu Koike ;

Hiroshi Matsui ;

Yasuhiro Shibata ;

Kazuto Ito ;

Kazuhiro Suzuki .

BMC Urology, 17

← 1 2 3 4 5 →